Intellectual Property

Neuronascent has submitted a number of provisional, PCT and National patent applications for the composition and use of families of structures that promote neurogenesis and neuron regeneration as therapeutics for neurodegenerative and psychiatric disorders. Patents as issued or as pending.

National patent filing on lead families, both Composition and Use

• March 2008 filed North America, Asia, Europe and Australia
• Issued by USPTO & Russia in 2011, S. Korea and China (limited claims) 2012, Australia and Canada 2013, Japan and Israel 2014, Second USPTO 2015
• Lead AD/PD (NNI‑362) and neuropsychiatric (NNI‑351) therapies covered

Extension of patents for lead candidates:

• METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC TYPE – US Continuation Pending, Submitted 12/2023
• METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC TYPE – EU, Asia, Canada, Australia Pending, Submitted 06/2022
• Orphan Drug FDA-designation for Fragile X syndrome (NNI-362)

National Patent filing on second family, both Composition and Use (NNI‑370‑PD)

• December 2009 filed in North America, Asia, Europe and Australia
• Claims issued by USPTO, Japan and EU covering neurodegenerative disease reversing agent